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The antiplatelet effect of aspirin may be compromised by an
enhanced platelet turnover, generating an increased fraction of
platelets that is able to form thromboxane within the dosing
intervals (usually 1 day). This may be of particular relevance
for patients undergoing CABG after cardiopulmonary bypass,
when postoperative platelet turnover is increased.
The present work examines whether the antiplatelet effect
of aspirin, which is based on the inhibition of platelet throm-
boxane production, may be impaired by an increased platelet
turnover. Determination of thromboxane in collagen-stimulat-
ed platelet-rich plasma after CABG showed a remarkable
enhancement of the capacity for thromboxane formation,
despite the fact that aspirin was administered at an antiplatelet
dose (100 mg once daily) that largely suppressed thrombox-
ane synthesis in healthy control subjects.
Aspirin is widely used to reduce graft thrombosis after
coronary artery bypass grafting (CABG).1 However, aspirin
appears to not always be an effective inhibitor of platelet func-
tion because considerable individual variations in the
antiplatelet effect of aspirin have been reported in patients
assigned to CABG.2
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Methods
Subjects and drug administration. This study was conduct-
ed in agreement with the Declaration of Helsinki and was
approved by the institutional ethics committee. Twenty-four
consecutive patients were included who had stable coronary
artery disease and underwent an elective CABG procedure
(2- to 3-vessel disease). Informed written consent was
obtained from each patient. Previous aspirin treatment was
terminated at least 7 days before CABG. Tablets (Aspirin 100
protect; Bayer AG, Leverkusen, Germany) containing 100 mg
of aspirin were administered every morning, starting on day 1
after the operation. Compliance was monitored by means of
tablet counts. For comparison, 5 healthy male volunteers (age
range, 27-45 years) received aspirin treatment (100 mg once
daily) over a duration of 5 days.
Measurement of platelet function. Venous blood (10 mL)
was collected in the morning (before aspirin ingestion) from
patients 1 day before and at days 1, 5, and 10 after CABG and
from volunteers immediately before and at day 5 of aspirin
treatment. Blood was drawn from the antecubital vein into
citrated (1:9) Vacutainer systems (Becton Dickinson,
Franklin Lakes, NJ). Platelet counts were determined by
means of automated counting. Immediately thereafter,
platelet-rich plasma was prepared, and collagen-induced (1
µg/mL collagen) aggregation and thromboxane formation
were determined, as previously described.3
Statistics. Data are mean values ± SEM. Statistical analy-
ses were performed with the Student t test and analysis of
variance for repeated measures, as required.
Results. CABG caused an early decrease in platelet counts
from 221 ± 8 × 103/µL (before CABG) to 160 ± 9 × 103/µL
(day 1 after CABG, P < .05). Thereafter, platelet counts
increased to 266 ± 14 × 103/µL at day 5 and 454 ± 31 ×
103/µL at day 10, indicating a substantial recovery of platelet
counts, which, at days 5 and 10, significantly exceeded the
control values obtained before CABG (P < .05).
Before CABG, 1 µg/mL collagen caused a considerable
platelet release of thromboxane (Fig 1). This was moderately
reduced at day 1 after CABG, as shown by a decay of throm-
boxane to 33% of the control value (P < .05). Nevertheless,
this inhibition was incomplete, and thromboxane formation
remained high at days 5 and 10 after CABG, corresponding
to 70% and 54% of the control values before the operation.
By contrast, the same dose of aspirin (100 mg/d) adminis-
tered to healthy volunteers for 5 days largely suppressed
thromboxane to 6% of the control value (P < .05, Fig 1).
This marginal inhibition of platelet thromboxane formation
by aspirin in patients undergoing CABG did not result in a
significant inhibition of platelet function, as shown by colla-
gen-induced platelet aggregation. At days 1, 5, and 10 after
CABG, platelet aggregation was 92% ± 8%, 103% ± 7%, and
91% ± 5% of the control value before the operation (100%).
Fig 1. Left, Concentrations of immunoreactive thromboxane (TX) B2 measured ex vivo after collagen-induced (1
µg/mL collagen) platelet activation. Measurements were obtained before CABG (con) and at days 1, 5, and 10 after
CABG. Aspirin (ASA) treatment (100 mg/d) started at day 1 after CABG. Data are mean values ± SEM (open cir-
cles) and individual measurements (filled circles). Right, Platelet thromboxane (TX) formation before (con) and
after aspirin (ASA) administration for 5 days in patients undergoing CABG (filled bars) in comparison with healthy
control subjects (open bars).
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By contrast, aspirin (100 mg/d for 5 days) significantly inhib-
ited platelet aggregation in healthy subjects to 33% ± 16% of
the pretreatment value (P < .05).
Discussion. The major finding of this study is that 100 mg
of aspirin, a dose known to be effective for the early
antithrombotic treatment after CABG,4,5 did not inhibit
platelet collagen-induced (1 µg/mL collagen) aggregation
and only incompletely inhibited platelet thromboxane syn-
thesis in patients subjected to CABG. The same dose and a
comparable duration of treatment (5 days) significantly
inhibited aggregation and almost completely abrogated
thromboxane formation of platelets from healthy subjects.
Hence, the early postoperative period after CABG is charac-
terized by a remarkable resistance against the antiplatelet
effect of aspirin.
It is important to recall, in this context, that cardiac opera-
tions with cardiopulmonary bypass, including the majority of
CABG procedures, activate and partially deplete circulating
platelets.6 In the present study this resulted in a fall of the
platelet count by about 25% at the first day after CABG.
Thereafter, platelet counts rapidly recovered. At day 10 after
CABG, platelet counts rose to more than 100% above the
value before CABG. Assuming a median platelet lifetime of
8 to 10 days, platelet regeneration was therefore augmented
at least 2-fold within the first 10 days after the operation.
Hence, immediately before ingestion of the daily aspirin
dose, a significant amount (ie, ≥10%) of circulating platelets
were probably competent for thromboxane formation. Given
that (1) platelet thromboxane synthesis needs to be blocked to
less than 10% to achieve efficient platelet inhibition7 and (2)
the plasma half-life of aspirin is short (ie, <30 minutes),8 cir-
cadian inhibition of platelet function may be incomplete. In
fact, the present study clearly shows that aspirin did not suf-
ficiently block thromboxane formation to allow for signifi-
cant platelet inhibition. One may argue that the method of
platelet aggregation measurements might not have been sen-
sitive enough to detect a moderate inhibitory effect of aspirin.
This, however, is unlikely because a comparable treatment of
healthy subjects significantly inhibited platelet aggregation in
this and earlier studies.9
Nevertheless, it is possible that additional causes of platelet
resistance against aspirin may be involved. For example, an
alternative aspirin-insensitive pathway for platelet thrombox-
ane formation, such as induction of the inducible isoform of
cyclooxygenase, may contribute.10 A follow-up trial has been
started to examine the pharmacodynamic properties and ade-
quate dosing intervals of aspirin after CABG.
The present study provides some implications for the use
of aspirin to reduce bypass thrombosis after CABG. First,
conventional doses of aspirin, such as 100 mg/d, appear inef-
fective to suppress platelet thromboxane formation in the
majority of patients. Second, at least one reason for this
aspirin resistance seems to be a considerably increased
recruitment of new platelets. The current results suggest that
the problem may be overcome by administration of aspirin in
more than one daily dose, which should prevent a critical cir-
cadian increase of the new thromboxane-forming platelet
fraction. Third, monitoring of the antiplatelet effect of aspirin
after CABG and potentially other states of enhanced platelet
regeneration appears worth considering. This would allow for
an optimized antiplatelet regimen in those patients who expe-
rience aspirin resistance, including the use of alternative
antiplatelet drugs.
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